Publications

Authors: William Polonsky, Malik Benamar, Lisbeth Carstensen, Melanie Davies, Anders Meller Donatsky, Edward Franek, Monika Kellerer, Athena Philis-Tsimikas, Ronald Goldenberg Abstract Aims: The ONWARDS phase 3a clinical trials evaluated once-weekly insulin icodec (icodec) versus once-daily basal insulin in type 2 diabetes. This analysis investigated the treatment-related experiences of participants from ONWARDS 5 and 2, and physicians from ONWARDS 1. Methods: Patient-reported outcomes

Authors: William Polonsky, Emily Soriano, Lisa Strycker, Lawrence Fisher. Abstract Background: Recent advances in diabetes care and technology, such as real-time continuous glucose monitoring, can help people live more freely, with more flexibility and fewer constraints, thereby enhancing quality of life (QOL). To date, there has been no validated means for measuring this key psychological dimension. We developed the Diabetes

Authors: Katharine Barnard-Kelly, David Marrero, Maartie de Wit, Frans Pouwer, Kamlesh Khunti, Norbert Hermans, Jessica Pierce, Lori Laffel, Richard Holt, Tadei Battelino, Diana Naranjo, Jacqueline Fosbury, Lawrence Fisher, William Polonsky, Jill Weissberg-Benchell, Korey Hood, Oliver Schnell, Laurel Messer, Thomas Danne, Revital Nimri, Soren Akovlund, Julia Mader, Jennifer Sherr, Desmond Schatz, Simon O’Neill, Emma Doble, Marissa Town, Karin Lange, Carine de

Authors: Lawrence Fisher, Susan Guzman, William Polonsky, Danielle Hessler Abstract Aims: Diabetes distress (DD) refers to the emotional and behavioural challenges associated with managing this demanding chronic disease over time. DD is alarmingly common and it has a significant impact on self-management behaviours and clinical outcomes. Thus, there is growing recognition that DD is a pressing problem that deserves careful attention

Authors: William Polonsky, Malik Benamar, Lisbeth Carstensen, Melanie Davies, Anders Meller Donatsky, Edward Franek, Monika Kellerer, Athena Philis-Tsimikas, Ronald Goldenberg Abstract Aims: The ONWARDS phase 3a clinical trials evaluated once-weekly insulin icodec (icodec) versus once-daily basal insulin in type 2 diabetes. This analysis investigated the treatment-related experiences of participants from ONWARDS 5 and 2, and physicians from ONWARDS 1. Methods: Patient-reported outcomes

Authors: Sarah A MacLeish, Korey K Hood, William H Polonsky, Jamie R Wood, Bruce W Bode, Gregory P Forlenza, Lori M Laffel, Bruce A Buckingham, Amy B Criego, Melissa J Schoelwer, Daniel J DeSalvo, Jennifer L Sherr, David W Hansen, Lindsey R Conroy, Lauren M Huyett, Todd E Vienneau, Trang T Ly; Omnipod 5 in Preschoolers Study Group Abstract Aim: Automated

Authors: Eden Miller, Steve Edelman, Carlos Campos, John E Anderson, Christopher G Parkin, William H Polonsky Abstract Objectives: To discuss the social, psychological, and access barriers that inhibit weight loss, and to propose steps and initiatives for addressing the growing obesity epidemic. Study design: Narrative review of the obesity epidemic in the US and associated racial/ethnic and socioeconomic disparities. Methods:

Authors: Michael Vallis , Lori Berard , Emmanuel Cosson , Finn Boerlum Kristensen, Fleur Levrat-Guillen 5, Nicolas Naiditch, Remi Rabasa-Lhoret , William Polonsky Abstract Objectives: Type 2 diabetes (T2D) management requires behavioural engagement to achieve optimal outcomes and continuous glucose monitoring (CGM) technologies may facilitate self-management. In this study, we describe the development and validation of a self-report instrument, the

Authors: Daniel J Moore, Natasha I Leibel, William Polonsky, and Henry Rodriguez Abstract Type 1 diabetes (T1D) is a complex, chronic autoimmune disease that affects over 1.6 million people in the United States. It is now understood that T1D may be undetected for many years while the disease progresses quietly without producing symptoms. T1D can be identified through diabetes-related autoantibody

Authors: M Kamruzzaman, M Horowitz, W H Polonsky, N J Talley, M A Borg, C K Rayner, K L Jones, C S Marathe Abstract Background and aims: Gastrointestinal (GI) symptoms, common in type 2 diabetes (T2D), are typically bothersome, socially embarrassing, and impact negatively on quality of life. They may also contribute to diabetes distress (DD), but this has never